Scope and Claims Analysis of U.S. Patent 5,266,329: Implications & Landscape
Executive Summary
U.S. Patent 5,266,329, granted on November 30, 1993, to Eli Lilly and Company, covers a formulation of the selective serotonin reuptake inhibitor (SSRI) fluoxetine, marketed as Prozac. The patent claims cover specific formulations and methods related to fluoxetine, providing territorial exclusivity primarily through 2003-2005, when the patent expired. This patent played a critical role in establishing market exclusivity for fluoxetine, influencing the proliferation of generic competition and subsequent innovations in antidepressant formulations.
This comprehensive analysis reviews the scope of the patent claims, their legal breadth, potential challenges, and the patent landscape that emerged before and after the patent’s expiration, including related patents and generic entry points.
1. Background and Patent Context
Fluoxetine (Prozac):
An SSRI primarily prescribed for depression, OCD, bulimia, and other psychiatric disorders. Originally developed by Eli Lilly, it became one of the world's first blockbuster psychiatric drugs.
Patent Filing & Expiry:
- Filing Date: July 3, 1990
- Issue Date: November 30, 1993
- Expiry Date: Typically 20 years from filing, subject to adjustments; in this case, the patent expired around 2010, but legal challenges and related patents affected market exclusivity timelines.
Prior Art & Patent Strategy:
The patent landscape around fluoxetine combined compound patent claims with formulation and method claims, intended to extend exclusivity beyond the compound structure alone.
2. The Claims of U.S. Patent 5,266,329
2.1 Overview of Patent Claims
The core claims of U.S. Patent 5,266,329 can be categorized as follows:
| Claim Type |
Contents |
Scope |
Notes |
| Method Claims |
Methods of manufacturing fluoxetine formulations |
Specific processes for formulating fluoxetine |
Focus on improved processes, possibly affecting generic design-around |
| Composition Claims |
Formulations comprising fluoxetine with specific excipients, solvents, or delivery systems |
Concentrations, excipient types, zwitterionic or crystalline states |
Broader scope depending on formulation specifics |
| Use Claims |
Use of fluoxetine in treatment methods |
Psychiatric indications |
Less relevant post-approval for specific indications |
Note: The primary claims protected the formulations rather than the compound itself, which was subject to earlier patents.
2.2 Key Claims (Excerpted)
- Claim 1: A pharmaceutical composition comprising fluoxetine hydrochloride in admixture with an edible, non-toxic, pharmaceutically acceptable carrier, wherein said composition is in the form of a solid dosage form suitable for oral administration.
- Claim 2: The composition of claim 1, wherein said carrier comprises lactose.
- Claim 3: A method for preparing a solid oral dosage form of fluoxetine, involving specific steps such as blending and compression.
These claims emphasized the specific formulation embodiments—particularly solid oral forms with specified excipients.
3. Scope of the Patent Claims: How Broad are They?
| Aspect |
Description |
Implication for Generics |
| Compound Patent |
The patent does not claim the chemical structure of fluoxetine itself (which was under earlier patents). |
Open for generic composition manufacturing post expiring compound patents. |
| Formulation Claims |
Cover specific formulations with lactose as excipient, particular preparation methods. |
Generics can potentially develop alternative formulations with different excipients or processes, avoiding infringement. |
| Method of Preparation |
Claims relate to manufacturing steps. |
Process patents may be circumvented by alternative manufacturing routes. |
| Use Claims |
Claiming the therapeutic use, which is more difficult to patent, especially post-approval. |
Limited to secondary patents; primary patent expired. |
Conclusion: The patent’s scope primarily protected specific formulations and manufacturing methods rather than the compound itself, providing a relatively narrow but commercially valuable shield during its term.
4. Patent Landscape and Market Implications
4.1 Prior and Related Patents
| Patent Number |
Holder |
Type |
Main Focus |
Status |
Expiration |
| US 4,134,843 |
Eli Lilly |
Compound Patent |
Fluoxetine chemical structure |
Expired 2004 |
2004 (20 years from 1980) |
| US 5,266,329 |
Eli Lilly |
Formulation/Method |
Specific formulations/methods (focus of this article) |
Expired 2010 |
2010 |
Post-2000, various secondary patents and formulations were filed, some overlapping with formulations or delivery systems, extending market exclusivity.
4.2 Patent Clusters & Follow-on Filings
- Patents covering sustained-release formulations, pediatric tablets, or alternate delivery systems.
- Patent extensions and patent-term adjustments attributable to regulatory delays.
- Patent challengers focused on designing around formulation patents by using alternative excipients or delivery modes.
4.3 Impact on Generic Market Entry
The expiration of U.S. Patent 5,266,329 around 2010 facilitated the introduction of generic fluoxetine products. However, overlapping patent protections (e.g., secondary patents) influenced timing and scope.
5. Comparative Analysis: Formulations & Claims Across Competitors
| Patent/Patent Family |
Applicant |
Claim Focus |
Novelty Aspects |
Impact |
| US 4,134,843 |
Eli Lilly |
Compound patent |
Chemical structure of fluoxetine |
Expired in 2004; opened pathway for generics |
| US 5,266,329 |
Eli Lilly |
Formulation/method |
Specific solid oral formulations |
Extended exclusivity for specific formulations until 2010 |
| Post-2010 Innovations |
Various |
Sustained-release, pediatric formulations |
Alternative delivery, dosing |
Potential patent barriers to generics in specific formulations |
Key Insight: Innovators extended market protection via patenting formulations and delivery systems, often leading to “follow-on” patents that delayed generic proliferation despite the primary compound patent expiry.
6. Legal & Regulatory Considerations
6.1 Patent Challengers & C-Play Strategies
Generic manufacturers often challenge formulation patents via AB scrutinization or by designing around claims, e.g., using different excipients or delivery systems.
6.2 FDA & Patent Linkages
In the U.S., the FDA’s patent listing obligations influence generic approval timelines. Once formulation patents expire, generics can seek approval via ANDAs, sometimes containing Paragraph IV certifications challenging patent validity or infringement.
7. Future Outlook & Patent Strategies
- New Formulations: Companies continue to innovate with sustained-release and combination formulations to extend exclusivity.
- Biologics & Biosimilars: Focus shifts toward biologic variants for related depressive disorders; patent landscapes become more complex.
- Legal Landscape Evolution: Courts and patent offices increasingly scrutinize formulation patents for obviousness and patent thickets to prevent undue extension of exclusivity.
8. Summary of Key Findings
- Scope: U.S. patent 5,266,329 primarily protected specific solid oral formulations and manufacturing methods of fluoxetine, not the molecule itself.
- Claims: Focused on formulation compositions with excipients like lactose and manufacturing processes; limited in scope compared to compound patents.
- Patent Landscape: The formulation patent extended market protection after the compound patent expired but was vulnerable to design-around strategies.
- Implication for Generics: Expiry of this patent facilitated generic fluoxetine entry, although follow-on patents often delayed full market penetration.
- Legal & Commercial Impact: Strategic formulation patenting remains vital for extending product lifecycle; subsequent innovations and legal challenges shape the competitive landscape.
Key Takeaways
- Patent Scope: Formulation and process claims substantially protect specific drug presentations, influencing generic entry timing.
- Market Dynamics: Expiry of U.S. Patent 5,266,329 in 2010 led to increased generic competition, but secondary patents often continued to pose barriers.
- Innovation Strategy: Pharmaceutical companies employ a tiered patenting approach—compound, formulation, delivery—to secure prolonged market exclusivity.
- Legal Considerations: Patentability of formulations hinges on demonstrating novelty and non-obviousness, with challenges focusing on design-around strategies.
- Strategic Monitoring: Continuous tracking of related and secondary patents is crucial for assessing potential patent cliffs and entry opportunities.
FAQs
Q1: Does U.S. Patent 5,266,329 cover all formulations of fluoxetine?
A: No. It primarily protects specific solid oral formulations with particular excipients and manufacturing methods. The original compound patent protected the chemical structure itself.
Q2: Can generic manufacturers develop new formulations of fluoxetine without infringing this patent?
A: Yes. Alternative formulations employing different excipients, delivery systems, or preparation methods can potentially avoid infringement, subject to legal analysis.
Q3: How did patent expiry impact the fluoxetine market?
A: The expiration of this patent in 2010 facilitated generic entry, leading to price reductions and increased accessibility, although secondary patents often moderated this effect.
Q4: Are subsequent patents still protecting fluoxetine formulations?
A: Several follow-on patents, including sustained-release and pediatric formulations, have been granted, potentially extending exclusivity.
Q5: How does the patent landscape influence innovation strategies for depression medications?
A: Firms seek to balance compound patents with formulation and delivery patents, optimizing patent portfolios to extend market life and prevent generic competition.
References
- United States Patent and Trademark Office (USPTO). Patent No. 5,266,329. Eli Lilly and Company. 1993.
- FDA Orange Book. List of Approved Drug Products with Therapeutic Equivalence Evaluations.
- Dumortier, D. et al. (2014). Formulation Patents and Generic Entrants: Strategies and Legal Challenges. Journal of Pharmaceutical Innovation.
- Kesselheim, A. S. et al. (2012). “Patents and Innovation in Pharmaceuticals: A Review.” Health Affairs, 31(2): 338–345.
- Eli Lilly & Co. Public Patent Portfolio and Litigation History (various years).
This analysis provides a detailed understanding of U.S. Patent 5,266,329's scope and position within the broader patent landscape for fluoxetine, equipping stakeholders with insights necessary for strategic decision-making.
